Published in Neurol Res Int on January 29, 2012
Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica. Acta Neuropathol Commun (2015) 0.93
Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2014) 0.87
Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. Rheumatol Int (2014) 0.84
Neuroprotection in a novel mouse model of multiple sclerosis. PLoS One (2013) 0.81
Venocentric Lesions: An MRI Marker of MS? Front Neurol (2013) 0.79
Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic. Curr Treat Options Neurol (2016) 0.79
Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
The ethics of placebo controlled clinical trials in NMO - A balance of risks. Mult Scler Relat Disord (2015) 0.75
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci (1997) 5.68
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology (2007) 3.83
Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain (2007) 3.64
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology (2009) 3.43
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
An open label study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 2.99
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain (2008) 2.96
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology (2005) 2.77
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol (1999) 2.69
The molecular basis of water transport in the brain. Nat Rev Neurosci (2003) 2.66
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Aquaporin-4 in the central nervous system: cellular and subcellular distribution and coexpression with KIR4.1. Neuroscience (2004) 2.54
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology (2003) 2.28
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26
Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol (1993) 2.23
Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun (2009) 2.20
Multiple sclerosis in the Japanese population. Lancet Neurol (2003) 2.15
Tolerability and safety of rituximab (MabThera). Cancer Treat Rev (2005) 2.15
Three distinct roles of aquaporin-4 in brain function revealed by knockout mice. Biochim Biophys Acta (2006) 2.03
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol (2010) 1.99
Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain (2007) 1.93
Water movements in the brain: role of aquaporins. Trends Neurosci (2007) 1.81
Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology (2009) 1.78
Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol (2010) 1.66
Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J (2008) 1.61
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A (2011) 1.60
Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology (1998) 1.53
Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology (2009) 1.52
Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci (2006) 1.52
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler (2007) 1.45
Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci (2010) 1.45
Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler (2009) 1.41
Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol (2004) 1.38
Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler (2007) 1.37
A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology (2009) 1.32
Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry (2006) 1.31
An epidemiological study of neuromyelitis optica in Cuba. J Neurol (2009) 1.30
MS and neuromyelitis optica in Martinique (French West Indies). Neurology (2001) 1.30
The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol (2009) 1.29
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol (2009) 1.27
Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation (2008) 1.27
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol (2006) 1.23
Neuromyelitis optica with hypothalamic involvement. Mult Scler (2005) 1.20
Optical coherence tomography in neuromyelitis optica. Arch Neurol (2008) 1.20
Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol (2009) 1.18
Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Scler (2010) 1.18
Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol (2007) 1.17
Familial neuromyelitis optica. Neurology (2010) 1.14
Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol (2007) 1.12
Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology (2011) 1.11
Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology (2009) 1.09
Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions. Mult Scler (2007) 1.08
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial (2009) 1.06
Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci (2004) 1.02
Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica. AJNR Am J Neuroradiol (2006) 1.01
Characterisation of the spectrum of demyelinating disease in Western Australia. J Neurol Neurosurg Psychiatry (2008) 1.00
Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol (2011) 0.99
MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology (1999) 0.98
Quantitative assessment of the cervical spinal cord damage in neuromyelitis optica using diffusion tensor imaging at 3 Tesla. J Magn Reson Imaging (2011) 0.97
Greatly attenuated experimental autoimmune encephalomyelitis in aquaporin-4 knockout mice. BMC Neurosci (2009) 0.97
Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler (2003) 0.97
Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol (2010) 0.96
Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology (2004) 0.95
Neuromyelitis optica in a mother and daughter. Arch Neurol (2007) 0.94
Extensive vasogenic edema of anti-aquaporin-4 antibody-related brain lesions. Mult Scler (2009) 0.91
Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand (2008) 0.90
Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol (2008) 0.89
Familial neuromyelitis optica (Devic's syndrome) with late onset in Japan. Neurology (2000) 0.89
Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med (2007) 0.89
Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey. Hong Kong Med J (2002) 0.87
Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Mult Scler (2009) 0.85
Neuromyelitis optica (Devic's syndrome) in two sisters. Clin Electroencephalogr (1982) 0.82
A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol (2003) 0.82
Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case report. BMC Neurol (2009) 0.82
Devic's syndrome and SLE: challenges in diagnosis and therapeutic possibilities based on two overlapping cases. Autoimmun Rev (2010) 0.80
Therapeutic efficacy of interferon β-1b in Japanese patients with optic-spinal multiple sclerosis. Tohoku J Exp Med (2011) 0.79
Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur J Neurol (2007) 0.79
Genome duplication in the teleost fish Tetraodon nigroviridis reveals the early vertebrate proto-karyotype. Nature (2004) 11.03
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc (2009) 2.32
Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain (2011) 2.21
Explicating an evidence-based, theoretically informed, mobile technology-based system to improve outcomes for people in recovery for alcohol dependence. Subst Use Misuse (2011) 1.84
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom (2012) 1.82
Ballistics for the neurosurgeon. Neurosurgery (2008) 1.75
Visceral leishmaniasis in a New York foxhound kennel. J Vet Intern Med (2002) 1.62
Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc (2007) 1.62
Use of MR cell tracking to evaluate targeting of glial precursor cells to inflammatory tissue by exploiting the very late antigen-4 docking receptor. Radiology (2012) 1.51
Adipose tissue macrophages: MR tracking to monitor obesity-associated inflammation. Radiology (2012) 1.49
Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol (2008) 1.46
Endoscopy by nonphysicians. Gastrointest Endosc (2009) 1.42
Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol (2012) 1.40
Integrated imaging approach with MEG and DTI to detect mild traumatic brain injury in military and civilian patients. J Neurotrauma (2009) 1.39
Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation (2008) 1.32
The role of mitochondrial porins and the permeability transition pore in learning and synaptic plasticity. J Biol Chem (2002) 1.31
Safe and effective intravenous thrombolysis for acute ischemic stroke caused by left atrial myxoma. J Stroke Cerebrovasc Dis (2009) 1.30
The 2004 Australian prison entrants' blood-borne virus and risk behaviour survey. Aust N Z J Public Health (2007) 1.29
An e-health solution for people with alcohol problems. Alcohol Res Health (2011) 1.23
Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health (2010) 1.18
Incidence and risk for acute hepatitis C infection during imprisonment in Australia. Eur J Epidemiol (2010) 1.18
Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma. Clin Gastroenterol Hepatol (2011) 1.14
Addressing Tobacco Through Organizational Change (ATTOC) in residential addiction treatment settings. Drug Alcohol Depend (2011) 1.07
In vivo biodistribution and biological impact of injected carbon nanotubes using magnetic resonance techniques. Int J Nanomedicine (2011) 1.04
Aboriginal and non-Aboriginal health differentials in Australian prisoners. Aust N Z J Public Health (2007) 1.04
Needle type and the risk of post-lumbar puncture headache in the outpatient neurology clinic. J Neurol Sci (2011) 1.02
Randomized multi-site trial of the Job Seekers' Workshop in patients with substance use disorders. Drug Alcohol Depend (2011) 1.01
Subclinical elevations of thyroid-stimulating hormone and assisted reproductive technology outcomes. Fertil Steril (2011) 0.97
Mortality among prisoners: how accurate is the Australian National Death Index? Aust N Z J Public Health (2005) 0.97
MEG source imaging method using fast L1 minimum-norm and its applications to signals with brain noise and human resting-state source amplitude images. Neuroimage (2013) 0.94
The role of endoscopy in the management of patients with diarrhea. Gastrointest Endosc (2010) 0.93
An automatic MEG low-frequency source imaging approach for detecting injuries in mild and moderate TBI patients with blast and non-blast causes. Neuroimage (2012) 0.93
Role of endoscopic ultrasound-guided fine-needle aspiration cytology, viscosity, and carcinoembryonic antigen in pancreatic cyst fluid. Endosc Ultrasound (2015) 0.92
Prisoners are at risk for hepatitis C transmission. Eur J Epidemiol (2004) 0.92
Sex behind the prison walls. Aust N Z J Public Health (2002) 0.90
Doxorubicin release triggered by alginate embedded magnetic nanoheaters: a combined therapy. Adv Mater (2010) 0.89
Role of endoscopic ultrasound during hospitalization for acute pancreatitis. World J Gastroenterol (2010) 0.89
Low serum vitamin D levels and recurrent inflammatory spinal cord disease. Arch Neurol (2011) 0.88
Predictors of increased radiation dose during percutaneous coronary intervention. Am J Cardiol (2009) 0.88
Smoking in prisons: the need for effective and acceptable interventions. J Public Health Policy (2010) 0.88
Substance abuse treatment clinician opinions and infectious disease service delivery. J Addict Dis (2009) 0.86
Health services for prisoners. BMJ (2011) 0.86
The other half of Hebb: K+ channels and the regulation of neuronal excitability in the hippocampus. Mol Neurobiol (2002) 0.85
Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori. World J Gastroenterol (2009) 0.85
Palliative Care Version 1.2016. J Natl Compr Canc Netw (2016) 0.85
Retrograde intramedullary nailing of femoral diaphyseal fractures caused by low-velocity gunshots. Orthopedics (2009) 0.84
Temporal differences in blood meal detection from the midguts of Triatoma infestans. Rev Inst Med Trop Sao Paulo (2012) 0.83
Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity. J Neuroimmunol (2010) 0.83
Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease? Therap Adv Gastroenterol (2013) 0.83
A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol (2011) 0.83
Assessment of CPR interruptions from transthoracic impedance during use of the LUCAS™ mechanical chest compression system. Resuscitation (2012) 0.82
Preimplantation diagnosis for neurofibromatosis. Reprod Biomed Online (2003) 0.82
Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol (2005) 0.81
Oral immunotherapy: ready for prime time? J Allergy Clin Immunol (2010) 0.81
Cardiac troponin elevation predicts mortality in patients undergoing orthotopic liver transplantation. J Transplant (2013) 0.80
n-Dodecyl-β-D-maltoside inhibits aggregation of human interferon-β-1b and reduces its immunogenicity. J Neuroimmune Pharmacol (2010) 0.80
Noninvasive monitoring of immunosuppressive drug efficacy to prevent rejection of intracerebral glial precursor allografts. Cell Transplant (2012) 0.80
Utility of dobutamine stress echocardiography as part of the pre-liver transplant evaluation: an evaluation of its efficacy. Clin Cardiol (2014) 0.80
Comparison of open versus minimally invasive craniosynostosis procedures from the perspective of the parent. J Craniofac Surg (2008) 0.79
Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis. BMC Neurol (2013) 0.79
Unusual submucosal tumor in the stomach. Diagnosis: Endometriosis. Gastroenterology (2011) 0.79
Prisoner and ex-prisoner health - improving access to primary care. Aust Fam Physician (2012) 0.78
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry (2011) 0.78
Magnetic nanoparticles for ultrafast mechanical control of inner ear hair cells. ACS Nano (2014) 0.78
Temozolomide and radiation for aggressive pediatric central nervous system malignancies. J Pediatr Hematol Oncol (2005) 0.77
Evidence for classic complement activity in neuromyelitis optica. Clin Neuropathol (2014) 0.77
Safer prescribing for prisoners. BMJ (2012) 0.77
Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016. MMWR Morb Mortal Wkly Rep (2016) 0.76
Coronary Interventions before Liver Transplantation Might Not Avert Postoperative Cardiovascular Events. Tex Heart Inst J (2015) 0.76
Moving beyond non-engagement on regulated needle-syringe exchange programs in Australian prisons. Harm Reduct J (2009) 0.76
Finding NMO: neuromyelitis optica in children. Neurology (2008) 0.76
Frequent and rapid progression of atrophy and intestinal metaplasia in gastric mucosa of patients with MALT lymphoma. Am J Gastroenterol (2006) 0.76
Auditory profile in superficial siderosis of the central nervous system: a prospective study. Otol Neurotol (2013) 0.76
What is the true clinicopathologic spectrum of neuromyelitis optica?-Reply. JAMA Neurol (2013) 0.75
Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines. Lasers Surg Med (2012) 0.75
Response: fidelity and flexibility. Addict Sci Clin Pract (2010) 0.75
Implementing an adapted version of the job seekers' workshop in a residential program for patients with substance use disorders. J Addict Med (2011) 0.75
The preoperative neurological evaluation. Neurohospitalist (2013) 0.75
Response: disconnects, triggers, and two-edged swords. Sci Pract Perspect (2007) 0.75
Is elevated gastric tissue NOX2 associated with lymphoma of mucosa-associated lymphoid tissue? Antioxid Redox Signal (2012) 0.75
Combined off-pump coronary artery bypass and abdominal aortic surgery is associated with low morbidity and mortality. Ann Vasc Surg (2003) 0.75
Guidance Document for the Prehospital Use of Tranexamic Acid in Injured Patients. Prehosp Emerg Care (2016) 0.75
783 Infant and Child Homicide from Abuse in Los Angeles County. Neurosurgery (2000) 0.75
Diagnosis of multiple sclerosis: Progress or confusion? Mult Scler Relat Disord (2022) 0.75
Gold nanocrescents for remotely measuring and controlling local temperature. Nanotechnology (2013) 0.75
Diagnosing CNS vasculitis: the case against empiric treatment. Neurologist (2012) 0.75
Reverse Distraction Cranioplasty for Treatment of Hydrocephalic Megalocephaly. J Craniofac Surg (2015) 0.75
The New World of Interaction Recording for Medical Practices. J Med Pract Manage (2016) 0.75
Fever and limp: thinking outside the box. Pediatr Emerg Care (2012) 0.75